Patents by Inventor Xiaocui GUO

Xiaocui GUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical Composition Comprising Mineralocorticoid Receptor Antagonist and Use Thereof
    Publication number: 20240016796
    Abstract: Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
    Type: Application
    Filed: September 26, 2023
    Publication date: January 18, 2024
    Inventors: Zhenhua Huang, Xiaocui Guo
  • Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
    Patent number: 11806344
    Abstract: Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: November 7, 2023
    Assignee: KBP Biosciences Pte. Ltd.
    Inventors: Zhenhua Huang, Xiaocui Guo
  • PHARMACEUTICAL COMPOSITION COMPRISING MINERALOCORTICOID RECEPTOR ANTAGONIST AND USE THEREOF
    Publication number: 20190201390
    Abstract: Provided are a pharmaceutical composition comprising a mineralocorticoid receptor antagonist and use thereof. When the pharmaceutical composition is orally administered to a patient having chronic kidney disease in need thereof, the effective and safe AUC ranges from 188 ng*h/mL to 3173 ng*h/mL, with bioavailability of 50% or more in mammals. When the pharmaceutical composition is orally administered at a daily dose of 0.1 to 1.0 mg to treat chronic kidney disease, the AUC is controlled at a safe and effective level.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 4, 2019
    Applicant: KBP BIOSCIENCES CO., LTD.
    Inventors: Zhenhua HUANG, Xiaocui GUO